Cell kinetics and repopulation parameters of irradiated xenograft tumours in SCID mice: comparison of two dose-fractionation regimens

Visualizing the effect of tumor microenvironments on radiation-induced cell kinetics in multicellular spheroids consisting of HeLa cells

In this study, we visualized the effect of tumor microenvironments on radiation-induced tumor cell kinetics. For this purpose, we utilized a multicellular spheroid model, with a diameter of ∼500 μm, consisting of HeLa cells expressing the fluorescent ubiquitination-based cell-cycle indicator (Fucci). In live spheroids, a confocal laser scanning microscope allowed us to clearly monitor cell kinetics at depths of up to 60 μm. Surprisingly, a remarkable prolongation of G2 arrest was observed in the outer region of the spheroid relative to monolayer-cultured cells. Scale, an aqueous reagent that renders tissues optically transparent, allowed visualization deeper inside spheroids. About 16 h after irradiation, a red fluorescent cell fraction, presumably a quiescent G0 cell fraction, became distinct from the outer fraction consisting of proliferating cells, most of which exhibited green fluorescence indicative of G2 arrest. Thereafter, the red cell fraction began to emit green fluorescence and remained in prolonged G2 arrest. Thus, for the first time, we visualized the prolongation of radiation-induced G2 arrest in spheroids and the differences in cell kinetics between the outer and inner fractions.

Topotecan Can Compensate for Protracted Radiation Treatment Time Effects in High Grade Glioma Xenografts*

PURPOSE

Several studies reported that prolongation of overall treatment time of fractionated radiotherapy reduces the chance of tumor control. In the present study, we hypothesize that combining topotecan with irradiation could compensate for this detrimental time effect on the radioresponse. Therefore, we investigated the efficiency of different schedules of topotecan (TPT), radiotherapy (RT) or concomitant combination TPT + RT.

METHODS AND MATERIALS

Experiments were performed in two human high-grade glioma xenograft models (U87 and GBM Nan1). TPT and RT were delivered at a total dose of 3 mg/kg and 40 Gy, respectively. For the TPT + RT groups, TPT was injected 5 min before radiation. Total radiation doses were delivered in 5, 10, 20, or 30 fractions over 1, 2, 4, or 6 weeks, respectively. The efficiency of TPT, RT, and TPT + RT was evaluated by tumor growth delay (TGD).

RESULTS

At this low total dose, and independent of the schedule, no efficacy was found in TPT-treated glioma xenografts. Conversely, radiotherapy-induced antitumor effect decreased with prolongation of treatment time. For TPT + RT combination, antitumor activity was not influenced by schedule, and tumor response was always comparable to those measured for the shortest and the most efficient irradiation schedule (i.e. 1 week). When treatment was delivered over 4 or 6 weeks in U87 glioma xenografts, therapeutic enhancement ratios reached 2.6 and 3.7, respectively. This indicated that the interaction between ionizing radiation and topotecan was synergistic.

CONCLUSION

The present study demonstrated that concomitant topotecan can compensate for the detrimental effect of treatment time protraction on radiotherapy efficacy in two malignant glioma xenografts.

Indium-111-bleomycin complex in squamous cell cancer xenograft tumors of nude mice

INTRODUCTION

Labeling of bleomycin with Auger-emitter Indium-111 increases cytotoxicity in squamous cell cancer (SCC) cell lines, as we have reported earlier. In this study, we investigated whether (111)In- BLMC is toxic and effective in vivo among SCC-xenografted mice. The influence of (111)InBLMC on the squamous cell carcinoma cell cycle stimulated interest.

MATERIALS AND METHODS

In an animal experiment, 10 SCC-xenografted mice were used, two for demonstrating targeting in gamma-camera images, eight for intraperitoneally receiving NaCl, BLM, or (111)InBLMC as therapy. After a 2-week follow-up, the tumors were analyzed for proliferation (mitoses, Ki-67). DNA flow cytometric analysis was carried out from tumor samples and three UT-SCC cell lines.

RESULTS

Tumors were observed on gamma-camera images in xenografted mice after a (111)InBLMC injection. The UT-SCC-19A-xenografted mouse had a T/non-T uptake of 7.54 at 4 hours after the injection. At the end of the therapeutic trial, the mice were alive. In spite of a small number of animals, our findings indicate that BLM and (111)InBLMC seem to be more effective than NaCl in reducing tumor size. The proliferative activity was strong in BLM and in (111)InBLMC groups, indicating regrowth of the tumors. In DNA analysis, the percentages of cells in the G2/M-phases increased after exposure to BLM and particularly to (111)InBLMC in all three cell lines.

CONCLUSIONS

The effect of BLM is preserved after the adding of Auger-emitter In-111. Tumor-seeking (111)InBLMC can be administered safely at tumor-decreasing concentrations in xenograft head and neck cancers. To demonstrate the antitumor effect of (111)InBLMC, the experiments should be extended to include a larger number of mice. BLM, and especially (111)InBLMC, seems to induce alteration in the cell cycle by producing a G2/M block. The verification of the result requires repeated in vitro experiments.

Repopulation of cancer cells during therapy: an important cause of treatment failure

Radiotherapy and chemotherapy are given in multiple doses, which are spaced out to allow the recovery of normal tissues between treatments. However, surviving cancer cells also proliferate during the intervals between treatments and this process of repopulation is an important cause of treatment failure. Strategies developed to overcome repopulation have improved clinical outcomes, and now new strategies to inhibit repopulation are emerging in parallel with advances in the understanding of underlying biological mechanisms.